Immunotherapy Archives

News and Trends 31 Oct 2018

Multiple Myeloma Antibody Therapy Achieves Positive Phase III Results

An antibody therapy for the blood cancer multiple myeloma achieved positive results at Phase III, decreasing the risk of the disease getting worse and patient death by 45% in a Phase III trial. The blockbuster antibody daratumumab, developed by Janssen using a license from the Danish company Genmab, was given to patients in combination with […]

October 31, 2018 - 2 minutesmins - By Jonathan Smith

Interview 25 Oct 2018

Mastering the Competitive World of Immuno-oncology

In recent years the oncology world has focused on using the immune system to target cancer, with CAR-T cell therapy and other success stories revolutionizing the field. Ulf Grawunder, CEO and founder of NBE Therapeutics, a company using antibody drug conjugates to target cancer, discussed how to navigate the competitive area of immuno-oncology at our […]

October 25, 2018 - 5 minutesmins - By Helen Albert

Innate Pharma Cancer immunotherapy header

News and Trends 22 Oct 2018

Innate’s Cancer Immunotherapy Combo Beats Standard Treatment Twofold

A combination cancer immunotherapy from French biotech Innate Pharma was twice as effective at treating recurrent squamous cell carcinoma as standard therapy in a Phase II trial. Squamous cell carcinoma is a head and neck cancer that forms lesions in the mucous membranes of body cavities such as the mouth, nose and throat. “Patients are […]

October 22, 2018 - 2 minutesmins - By Jonathan Smith

Immunicum cancer immunotherapy dendritic cell

News and Trends 16 Oct 2018

Cancer Immunotherapy Biotech Raises €34M on Nasdaq Stockholm

The Swedish biotech Immunicum has issued shares worth up to almost €34M on Nasdaq Stockholm, in an effort to accelerate the development of its cancer immunotherapy. Immunicum plans to use most of the funding to run a Phase Ib/II clinical trial that will test its lead cell therapy candidate in combination with checkpoint inhibitors to […]

October 16, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 10 Oct 2018

Cancer Immunotherapy Phase I on Hold After Patient Death

The German biotech Affimed has halted two Phase I trials of its cancer immunotherapy after three patients suffered neurotoxicity due to the treatment, causing the death of one of them. Affimed was testing its immunotherapy AFM11 in 33 patients diagnosed with white blood cell cancer in two Phase I trials. One trial tested the therapy […]

October 10, 2018 - 2 minutesmins - By Jonathan Smith

Boehringer Ingelheim ViraTherapeutics oncolytic virus

More News! 13 Sep 2018

Boehringer Ingelheim Acquires Oncolytic Virus Biotech Company

Boehringer Ingelheim is paying €210M to acquire all the remaining shares of ViraTherapeutics, an Austrian biotech company developing oncolytic viral therapies for cancer. ViraTherapeutics develops cancer therapies based on viruses that selectively kill tumor cells, based on the principle that cancer cells show defective mechanisms to defend themselves against viruses that are not able to […]

September 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Helen Tayton Martin Adaptimmune interview

Interview 11 Sep 2018

How To Break Into The Crowded Immuno-Oncology Space

The field of immuno-oncology promises to make anti-cancer treatments more effective than ever. But in this crowded field, many companies struggle to make therapies that not only are effective and safe, but that can also be scaled-up, manufactured and commercialized. Helen Tayton-Martin, Chief Business Officer at the biotech company Adaptimmune, shares her advice on how […]

September 11, 2018 - 6 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Aug 2018

Affimed Collaborates with Genentech in Cancer Immunotherapy Deal Worth €4.4B

The German biotech will partner with Genentech, part of the Roche Group, to develop targeted cancer therapies that engage both innate and adaptive immune cells. Affimed will receive €82M ($96M) upfront from the US giant to develop its immunotherapy ROCK (Redirected Optimized Cell Killing) platform, which uses both natural killer cells and T-cells to target […]

August 29, 2018 - 2 minutesmins - By Helen Albert

News and Trends 28 Aug 2018

Update: Gilead and Novartis’s CAR T-Cell Therapies Approved in Europe

Update: Following on from earlier approvals in the US, the European Commission announced it has given marketing approval for both Gilead’s Yescarta and Novartis’s Kymriah for treatment of patients with various forms of blood cancer. Yescarta (axicabtagene ciloleucel) can be used to treat adults with a relapsed or refractory form of the blood cancer diffuse large […]

August 28, 2018 - 4 minutesmins - By Editorial Team

News and Trends 26 Jul 2018

Replimune’s €85M IPO set to Boost Oncolytic Immunotherapy Pipeline

The US-UK biotech completed its $100M (€85M) IPO on the NASDAQ stock exchange to further develop ‘oncolytic’ immunotherapies that use the herpes virus to target and attack tumor tissue. Replimune’s immunotherapies use the virus to deliver proteins into tumor tissue that help it fuse with the tumor cells. When the virus fuses to tumor cells, it activates […]

July 26, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 12 Jul 2018

Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies

Genmab is partnering with the German company Immatics to develop immunotherapies directed against three cancer targets. Genmab has offered Immatics, based in Tuebingen, Germany, an upfront payment of $54M (€46M) in addition to milestone payments worth up to $550M (€470M) for each product. Genmab has a market cap of €60Bn ($70Bn). The funding will be […]

July 12, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 29 Jun 2018

Update: Yet Another ADC Company Makes Bank, This Time in Series B

Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M), reaching a total of 40M CHF (€34.6M) for the round. Novo Holdings joins the Boehringer Ingelheim Venture Fund and the PPF Capital Partners Fund as a major shareholder of the Swiss biotech, which continues to develop its ADCs for improved […]

June 29, 2018 - 3 minutesmins - By Editorial Team

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Multiple Myeloma Antibody Therapy Achieves Positive Phase III Results

Mastering the Competitive World of Immuno-oncology

Innate’s Cancer Immunotherapy Combo Beats Standard Treatment Twofold

Cancer Immunotherapy Biotech Raises €34M on Nasdaq Stockholm

Cancer Immunotherapy Phase I on Hold After Patient Death

Boehringer Ingelheim Acquires Oncolytic Virus Biotech Company

How To Break Into The Crowded Immuno-Oncology Space

Affimed Collaborates with Genentech in Cancer Immunotherapy Deal Worth €4.4B

Update: Gilead and Novartis’s CAR T-Cell Therapies Approved in Europe

Replimune’s €85M IPO set to Boost Oncolytic Immunotherapy Pipeline

Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies

Update: Yet Another ADC Company Makes Bank, This Time in Series B

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!